新加坡国立眼科中心Shamira Perera(医学和外科学士)说，一种新型缓释曲伏前列素泪小点栓(TPP)可实现30天治疗性药物给药水平，有可能成为局部滴眼液的一种替代方法，特别是对于依从性差的患者而言。他介绍了TPP可行性研究(纳入17例眼高压或开角型青光眼患者)的结果。TPP包括一个基于干聚乙二醇的杆状水凝胶。药物嵌于水凝胶内。扩张泪小点后，将TPP插入上或下泪小点。TPP随后释放药物至眼睛表面。

　　PA009

　　Evaluation of a Sustained Release Travoprost Punctum Plug for IOP Reduction

　　Purpose: To appraise a novel sustained-release travoprost punctum plug (TP) (Ocular Therapeutix; Mass., USA) for retention and IOP reduction in ocular hypertensive or glaucoma patients.

　　Methods: Twenty patients (up to n = 40 eyes) at 2 sites in Singapore were implanted with TP in either the upper or lower puncta and prospectively followed over 30 days.

　　Results: The mean IOP reduction over 10 days was approximately 6 mmHg from 25.9 (± 2.1) to 19.3 (± 3.4) for 7 subjects. The IOP reduction was sustained in the 2 subjects that exited the study after 30 days. The TP was easy to insert, and preliminary results suggest good retention.

　　Conclusion: The TP achieves therapeutic delivery levels over 30 days. Circumventing poor compliance, the TP shows promise as an alternative to topical drops.